RxDoctor Payments Data

Denise Burns Legros

Corneal and Contact Management · Melbourne, FLNPI 1730297185

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $4,746 of the $5,731 with a category attached, or 82.8%. It is spread thinly across 19 manufacturers, the largest accounting for just 15.1% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2019 at $2,197 and has fallen 91.0% since, to $198 in 2025.

$5,731in general payments, 2019–2025

Across 106 payments — averaging $54.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$865
  • Johnson & Johnson Vision Care, Inc.$818
  • Visionary Optics LLC$810
  • AbbVie$809
  • Coopervision Inc.$740
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$387
  • plus $1K from 13 others

What the payments were for

  • Consulting fees$1753%
  • Food & beverage$4,74683%
  • Gifts$81014%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,731 in reported general payments places this provider in the 85th percentile of 67 corneal and contact management providers in Florida.

See all corneal and contact management providers in Florida

Medicare billing

Part B allowed, 2024
$74,045
Medicare patients
373
Services billed
807

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RestasisCyclosporine19$15,097
LumiganBimatoprost17$11,295
Latanoprost157$2,528
Brimonidine Tartrate23$591
Tobramycin-DexamethasoneTobramycin/Dexamethasone15$549
Timolol Maleate34$403

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan$809$26,39236 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 67 corneal and contact management providers in Florida.

Other corneal and contact management in Melbourne

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →